Shopping Cart 0
Cart Subtotal
AED 0

Migraine - Pipeline Review, H2 2018

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
AED 7340

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Site License
AED 14680

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
AED 22020
  • Details
  • Table Of Content
  • Licence Rights
  • Section Purchase
  • Products and Companies

Details

Migraine-Pipeline Review, H2 2018

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Migraine-Pipeline Review, H2 2018, provides an overview of the Migraine (Central Nervous System) pipeline landscape.

Migraine is a disorder characterized by repeated attacks of severe headache. A migraine headache causes throbbing or pulsating pain, usually on only one side of the head. These headaches are often associated with nausea, vomiting, and extreme sensitivity to light and sound. Symptoms include problems speaking, tingling in face, arms, and shoulders, pain behind one of the eyes and pain that gets worse with routine physical activity.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Migraine-Pipeline Review, H2 2018, provides comprehensive information on the therapeutics under development for Migraine (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Migraine (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Migraine and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 4, 13, 11, 16, 1, 24, 4 and 3 respectively. Similarly, the Universities portfolio in Phase II, Phase I and Preclinical stages comprises 1, 1 and 2 molecules, respectively.

Migraine (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Migraine (Central Nervous System).

- The pipeline guide reviews pipeline therapeutics for Migraine (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.

- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

- The pipeline guide reviews key companies involved in Migraine (Central Nervous System) therapeutics and enlists all their major and minor projects.

- The pipeline guide evaluates Migraine (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

- The pipeline guide reviews latest news related to pipeline therapeutics for Migraine (Central Nervous System)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

- Find and recognize significant and varied types of therapeutics under development for Migraine (Central Nervous System).

- Classify potential new clients or partners in the target demographic.

- Develop tactical initiatives by understanding the focus areas of leading companies.

- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

- Formulate corrective measures for pipeline projects by understanding Migraine (Central Nervous System) pipeline depth and focus of Indication therapeutics.

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 2

Introduction 5

Migraine-Overview 6

Migraine-Therapeutics Development 7

Migraine-Therapeutics Assessment 20

Migraine-Companies Involved in Therapeutics Development 30

Migraine-Drug Profiles 49

Migraine-Dormant Projects 205

Migraine-Discontinued Products 210

Migraine-Product Development Milestones 211

Appendix 222


List Of Figure

List of Figures

Number of Products under Development for Migraine, H2 2018 15

Number of Products under Development by Companies, H2 2018 16

Number of Products under Development by Universities/Institutes, H2 2018 21

Number of Products by Top 10 Targets, H2 2018 28

Number of Products by Stage and Top 10 Targets, H2 2018 28

Number of Products by Top 10 Mechanism of Actions, H2 2018 31

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2018 31

Number of Products by Top 10 Routes of Administration, H2 2018 34

Number of Products by Stage and Top 10 Routes of Administration, H2 2018 34

Number of Products by Molecule Types, H2 2018 36

Number of Products by Stage and Molecule Types, H2 2018 36


List Of Table

List of Tables

Number of Products under Development for Migraine, H2 2018 15

Number of Products under Development by Companies, H2 2018 17

Number of Products under Development by Universities/Institutes, H2 2018 21

Products under Development by Companies, H2 2018 22

Products under Development by Universities/Institutes, H2 2018 27

Number of Products by Stage and Target, H2 2018 29

Number of Products by Stage and Mechanism of Action, H2 2018 32

Number of Products by Stage and Route of Administration, H2 2018 35

Number of Products by Stage and Molecule Type, H2 2018 37

Migraine-Pipeline by Abide Therapeutics Inc, H2 2018 38

Migraine-Pipeline by Achelios Therapeutics Inc, H2 2018 38

Migraine-Pipeline by Acorda Therapeutics Inc, H2 2018 39

Migraine-Pipeline by Alder Biopharmaceuticals Inc, H2 2018 39

Migraine-Pipeline by Allergan Plc, H2 2018 40

Migraine-Pipeline by Amgen Inc, H2 2018 40

Migraine-Pipeline by AOBiome LLC, H2 2018 41

Migraine-Pipeline by Aralez Pharmaceuticals Inc, H2 2018 41

Migraine-Pipeline by Astellas Pharma Inc, H2 2018 42

Migraine-Pipeline by Avanir Pharmaceuticals Inc, H2 2018 42

Migraine-Pipeline by Axsome Therapeutics Inc, H2 2018 42

Migraine-Pipeline by Biohaven Pharmaceutical Holding Company Ltd, H2 2018 43

Migraine-Pipeline by BioHealthonomics Inc, H2 2018 43

Migraine-Pipeline by Blackthorn Therapeutics Inc, H2 2018 44

Migraine-Pipeline by Charleston Laboratories Inc, H2 2018 44

Migraine-Pipeline by Corium International Inc, H2 2018 45

Migraine-Pipeline by Crossject SA, H2 2018 45

Migraine-Pipeline by Eli Lilly and Co, H2 2018 46

Migraine-Pipeline by Heptares Therapeutics Ltd, H2 2018 46

Migraine-Pipeline by Impel NeuroPharma Inc, H2 2018 46

Migraine-Pipeline by InKemia IUCT Group SA, H2 2018 47

Migraine-Pipeline by InStar Technologies AS, H2 2018 47

Migraine-Pipeline by Ionis Pharmaceuticals Inc, H2 2018 48

Migraine-Pipeline by Klaria Pharma Holding AB, H2 2018 48

Migraine-Pipeline by Medy-Tox Inc, H2 2018 49

Migraine-Pipeline by Merck & Co Inc, H2 2018 49

Migraine-Pipeline by Mylan NV, H2 2018 50

Migraine-Pipeline by NAL Pharmaceuticals Ltd, H2 2018 50

Migraine-Pipeline by Pharmaleads SA, H2 2018 50

Migraine-Pipeline by Pivot Pharmaceuticals Inc, H2 2018 51

Migraine-Pipeline by Promius Pharma LLC, H2 2018 51

Migraine-Pipeline by Revance Therapeutics Inc, H2 2018 52

Migraine-Pipeline by Sarfez Pharmaceuticals Inc, H2 2018 52

Migraine-Pipeline by Shin Nippon Biomedical Laboratories Ltd, H2 2018 53

Migraine-Pipeline by Sorrento Therapeutics Inc, H2 2018 53

Migraine-Pipeline by Suda Pharmaceuticals Ltd, H2 2018 54

Migraine-Pipeline by Teva Pharmaceutical Industries Ltd, H2 2018 54

Migraine-Pipeline by Trevena Inc, H2 2018 55

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License: 
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:  
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Products and Companies

Products

Migraine Therapeutic Products under Development, Key Players in Migraine Therapeutics, Migraine Pipeline Overview, Migraine Pipeline, Migraine Pipeline Assessment


Companies

Abide Therapeutics Inc

Achelios Therapeutics Inc

Acorda Therapeutics Inc

Alder Biopharmaceuticals Inc

Allergan Plc

Amgen Inc

AOBiome LLC

Aralez Pharmaceuticals Inc

Astellas Pharma Inc

Avanir Pharmaceuticals Inc

Axsome Therapeutics Inc

Biohaven Pharmaceutical Holding Company Ltd

BioHealthonomics Inc

Blackthorn Therapeutics Inc

Charleston Laboratories Inc

Corium International Inc

Crossject SA

Eli Lilly and Co

Heptares Therapeutics Ltd

Impel NeuroPharma Inc

InKemia IUCT Group SA

InStar Technologies AS

Ionis Pharmaceuticals Inc

Klaria Pharma Holding AB

Medy-Tox Inc

Merck & Co Inc

Mylan NV

NAL Pharmaceuticals Ltd

Pharmaleads SA

Pivot Pharmaceuticals Inc

Promius Pharma LLC

Revance Therapeutics Inc

Sarfez Pharmaceuticals Inc

Shin Nippon Biomedical Laboratories Ltd

Sorrento Therapeutics Inc

Suda Pharmaceuticals Ltd

Teva Pharmaceutical Industries Ltd

Trevena Inc

TrioxBio Inc

Xenon Pharmaceuticals Inc

Xoc Pharmaceuticals Inc

Zosano Pharma Corp

Migraine-Pipeline Review, H2 2018

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Migraine-Pipeline Review, H2 2018, provides an overview of the Migraine (Central Nervous System) pipeline landscape.

Migraine is a disorder characterized by repeated attacks of severe headache. A migraine headache causes throbbing or pulsating pain, usually on only one side of the head. These headaches are often associated with nausea, vomiting, and extreme sensitivity to light and sound. Symptoms include problems speaking, tingling in face, arms, and shoulders, pain behind one of the eyes and pain that gets worse with routine physical activity.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Migraine-Pipeline Review, H2 2018, provides comprehensive information on the therapeutics under development for Migraine (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Migraine (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Migraine and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 4, 13, 11, 16, 1, 24, 4 and 3 respectively. Similarly, the Universities portfolio in Phase II, Phase I and Preclinical stages comprises 1, 1 and 2 molecules, respectively.

Migraine (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Migraine (Central Nervous System).

- The pipeline guide reviews pipeline therapeutics for Migraine (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.

- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

- The pipeline guide reviews key companies involved in Migraine (Central Nervous System) therapeutics and enlists all their major and minor projects.

- The pipeline guide evaluates Migraine (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

- The pipeline guide reviews latest news related to pipeline therapeutics for Migraine (Central Nervous System)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

- Find and recognize significant and varied types of therapeutics under development for Migraine (Central Nervous System).

- Classify potential new clients or partners in the target demographic.

- Develop tactical initiatives by understanding the focus areas of leading companies.

- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

- Formulate corrective measures for pipeline projects by understanding Migraine (Central Nervous System) pipeline depth and focus of Indication therapeutics.

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

READ MORE

Scope

Table of Contents

Table of Contents 2

Introduction 5

Migraine-Overview 6

Migraine-Therapeutics Development 7

Migraine-Therapeutics Assessment 20

Migraine-Companies Involved in Therapeutics Development 30

Migraine-Drug Profiles 49

Migraine-Dormant Projects 205

Migraine-Discontinued Products 210

Migraine-Product Development Milestones 211

Appendix 222


List Of Figure

List of Figures

Number of Products under Development for Migraine, H2 2018 15

Number of Products under Development by Companies, H2 2018 16

Number of Products under Development by Universities/Institutes, H2 2018 21

Number of Products by Top 10 Targets, H2 2018 28

Number of Products by Stage and Top 10 Targets, H2 2018 28

Number of Products by Top 10 Mechanism of Actions, H2 2018 31

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2018 31

Number of Products by Top 10 Routes of Administration, H2 2018 34

Number of Products by Stage and Top 10 Routes of Administration, H2 2018 34

Number of Products by Molecule Types, H2 2018 36

Number of Products by Stage and Molecule Types, H2 2018 36


List Of Table

List of Tables

Number of Products under Development for Migraine, H2 2018 15

Number of Products under Development by Companies, H2 2018 17

Number of Products under Development by Universities/Institutes, H2 2018 21

Products under Development by Companies, H2 2018 22

Products under Development by Universities/Institutes, H2 2018 27

Number of Products by Stage and Target, H2 2018 29

Number of Products by Stage and Mechanism of Action, H2 2018 32

Number of Products by Stage and Route of Administration, H2 2018 35

Number of Products by Stage and Molecule Type, H2 2018 37

Migraine-Pipeline by Abide Therapeutics Inc, H2 2018 38

Migraine-Pipeline by Achelios Therapeutics Inc, H2 2018 38

Migraine-Pipeline by Acorda Therapeutics Inc, H2 2018 39

Migraine-Pipeline by Alder Biopharmaceuticals Inc, H2 2018 39

Migraine-Pipeline by Allergan Plc, H2 2018 40

Migraine-Pipeline by Amgen Inc, H2 2018 40

Migraine-Pipeline by AOBiome LLC, H2 2018 41

Migraine-Pipeline by Aralez Pharmaceuticals Inc, H2 2018 41

Migraine-Pipeline by Astellas Pharma Inc, H2 2018 42

Migraine-Pipeline by Avanir Pharmaceuticals Inc, H2 2018 42

Migraine-Pipeline by Axsome Therapeutics Inc, H2 2018 42

Migraine-Pipeline by Biohaven Pharmaceutical Holding Company Ltd, H2 2018 43

Migraine-Pipeline by BioHealthonomics Inc, H2 2018 43

Migraine-Pipeline by Blackthorn Therapeutics Inc, H2 2018 44

Migraine-Pipeline by Charleston Laboratories Inc, H2 2018 44

Migraine-Pipeline by Corium International Inc, H2 2018 45

Migraine-Pipeline by Crossject SA, H2 2018 45

Migraine-Pipeline by Eli Lilly and Co, H2 2018 46

Migraine-Pipeline by Heptares Therapeutics Ltd, H2 2018 46

Migraine-Pipeline by Impel NeuroPharma Inc, H2 2018 46

Migraine-Pipeline by InKemia IUCT Group SA, H2 2018 47

Migraine-Pipeline by InStar Technologies AS, H2 2018 47

Migraine-Pipeline by Ionis Pharmaceuticals Inc, H2 2018 48

Migraine-Pipeline by Klaria Pharma Holding AB, H2 2018 48

Migraine-Pipeline by Medy-Tox Inc, H2 2018 49

Migraine-Pipeline by Merck & Co Inc, H2 2018 49

Migraine-Pipeline by Mylan NV, H2 2018 50

Migraine-Pipeline by NAL Pharmaceuticals Ltd, H2 2018 50

Migraine-Pipeline by Pharmaleads SA, H2 2018 50

Migraine-Pipeline by Pivot Pharmaceuticals Inc, H2 2018 51

Migraine-Pipeline by Promius Pharma LLC, H2 2018 51

Migraine-Pipeline by Revance Therapeutics Inc, H2 2018 52

Migraine-Pipeline by Sarfez Pharmaceuticals Inc, H2 2018 52

Migraine-Pipeline by Shin Nippon Biomedical Laboratories Ltd, H2 2018 53

Migraine-Pipeline by Sorrento Therapeutics Inc, H2 2018 53

Migraine-Pipeline by Suda Pharmaceuticals Ltd, H2 2018 54

Migraine-Pipeline by Teva Pharmaceutical Industries Ltd, H2 2018 54

Migraine-Pipeline by Trevena Inc, H2 2018 55

Single User License:
Report can be used by individual purchaser only

Site License: 
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:  
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Products

Migraine Therapeutic Products under Development, Key Players in Migraine Therapeutics, Migraine Pipeline Overview, Migraine Pipeline, Migraine Pipeline Assessment


Companies

Abide Therapeutics Inc

Achelios Therapeutics Inc

Acorda Therapeutics Inc

Alder Biopharmaceuticals Inc

Allergan Plc

Amgen Inc

AOBiome LLC

Aralez Pharmaceuticals Inc

Astellas Pharma Inc

Avanir Pharmaceuticals Inc

Axsome Therapeutics Inc

Biohaven Pharmaceutical Holding Company Ltd

BioHealthonomics Inc

Blackthorn Therapeutics Inc

Charleston Laboratories Inc

Corium International Inc

Crossject SA

Eli Lilly and Co

Heptares Therapeutics Ltd

Impel NeuroPharma Inc

InKemia IUCT Group SA

InStar Technologies AS

Ionis Pharmaceuticals Inc

Klaria Pharma Holding AB

Medy-Tox Inc

Merck & Co Inc

Mylan NV

NAL Pharmaceuticals Ltd

Pharmaleads SA

Pivot Pharmaceuticals Inc

Promius Pharma LLC

Revance Therapeutics Inc

Sarfez Pharmaceuticals Inc

Shin Nippon Biomedical Laboratories Ltd

Sorrento Therapeutics Inc

Suda Pharmaceuticals Ltd

Teva Pharmaceutical Industries Ltd

Trevena Inc

TrioxBio Inc

Xenon Pharmaceuticals Inc

Xoc Pharmaceuticals Inc

Zosano Pharma Corp